Revenue Breakdown
Composition ()
No data
Revenue Streams
Exelixis Inc (EXEL) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is CABOMETYX, accounting for 90.3% of total sales, equivalent to $539.88M. Other significant revenue streams include License revenues and COMETRIQ. Understanding this composition is critical for investors evaluating how EXEL navigates market cycles within the Biotechnology & Medical Research industry.
Profitability & Margins
Evaluating the bottom line, Exelixis Inc maintains a gross margin of 95.58%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 39.41%, while the net margin is 40.85%. These profitability ratios, combined with a Return on Equity (ROE) of 35.53%, provide a clear picture of how effectively EXEL converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, EXEL competes directly with industry leaders such as JAZZ and IBRX. With a market capitalization of $10.66B, it holds a significant position in the sector. When comparing efficiency, EXEL's gross margin of 95.58% stands against JAZZ's 73.01% and IBRX's 99.00%. Such benchmarking helps identify whether Exelixis Inc is trading at a premium or discount relative to its financial performance.
